Robert Jordan

Robert Jordan, PMP, is Palatin’s Senior Vice President of Program Operations. Robert’s responsibilities during his 16 years with Palatin have included clinical and program development, alliance management, regulatory operations, data publication and communication strategy, key opinion leading relations, and business development.

Robert has successfully managed several drug programs, including Palatin’s development of Vyleesi® from phase 2 through NDA submission and FDA approval in 2019 as the only as-needed treatment for hypoactive sexual desire disorder (HSDD). Robert oversees all of Palatin’s drug development programs as well as leads clinical operations.